FiercePharma

Vertex Receives Complete Response Letter from U.S. FDA for Use of KALYDECO® (ivacaftor) in People with Cystic Fibrosis Ages 2 and Older with One of 23 Residual Function Mutations

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its ...
Boston.com

Vertex’s Kalydeco drug approved for rare form of cystic fibrosis

In a big win for Cambridge-based Vertex Pharmaceuticals, the US Food and Drug Administration today approved the company’s drug Kalydeco (ivacaftor) to treat a rare form of cystic fibrosis. The drug is ...
bdnews24

Vertex cystic fibrosis drug improves lung function

LOS ANGELES, March 27 (bdnews24.com/Reuters) - Vertex Pharmaceuticals Inc said on Thursday that a small study of its experimental cystic fibrosis drug showed that two ...